Novavax, Inc.
NVAXNovavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus (RSV), avian flu, shingles, Clostridioides difficile, and malaria.
Drugs in Pipeline
30
Phase 3 Programs
14
Upcoming Catalysts
1
Next Catalyst
Aug 5, 2026
6wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)
COVID-19
RSV-F Vaccine
Respiratory Syncytial Virus (RSV)
NVX-CoV2705 Vaccine
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
NVX-CoV2373
SARS-CoV-2 Infection
CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant
COVID-19
SARS-CoV-2 rS/Matrix M1-Adjuvant
SARS-CoV-2 Infection
RSV F vaccine with adjuvant
Respiratory Syncytial Virus Infections
SARS-CoV-2 rS antigen/Matrix-M Adjuvant
COVID-19
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period)
SARS-CoV Infection
NVX-CoV2373 (5μg)
COVID-19
NanoFlu
Influenza, Human
XBB.1.5 Vaccine (Booster)
COVID-19
NVX-CoV2515
COVID-19
NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine
COVID-19
Fluzone HD - Day 0
Influenza
SARS-CoV-2 rS/Matrix-M1 Adjuvant
SARS-CoV-2 Infection
Novavax Quadrivalent vaccine
Influenza
Influenza VLP Vaccine
Influenza
SARS-CoV-2 rS - Phase 1
COVID-19
Quadrivalent VLP Vaccine
Influenza
Influenza VLP Vaccine (recombinant)
Influenza
H5N1 VLP Vaccine
Pandemic Influenza
ICC Vaccine
SARS-CoV Infection
Low dose RSV F Antigen
Respiratory Syncytial Virus Infections
RSV F vaccine (0.5mL injection)
Respiratory Syncytial Virus Infections
Low dose RSV-F Vaccine with Adjuvant
Respiratory Syncytial Virus (RSV)
qNIV Vaccine with Matrix-M Adjuvant
COVID-19
A/H1N1 2009 Influenza VLP Vaccine
Seasonal Influenza
Monovalent Avian Influenza VLP (H7N9)
Influenza (Pandemic)
RSV F Vaccine with Aluminum Phosphate Adjuvant
Respiratory Syncytial Viruses